ApoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL

Journal of Lipid Research

Volumn 55, Issue 7, 2014, Pages 1310-1323

  Fotakis, Panagiotis ^a,b,c   Vezeridis, Alexander ^a   Dafnis, Ioannis ^d   Chroni, Angeliki ^d   Kardassis, Dimitris ^b,c   Zannis, Vassilis I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CRETE   (Greece)

^c INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^d National Center for Research Demokritos   (Greece)

Author keywords

Apolipoprotein E3; Cholesterol acyl transferase; Dominant type III hyperlipoproteinemia; Gene transfer; High density lipoprotein; Hypertriglyceridemia; Lecithin; Lipoprotein lipase; Recombinant adenovirus

Indexed keywords

APOLIPOPROTEIN E3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DENATURATION; DENSITY GRADIENT CENTRIFUGATION; DYSLIPIDEMIA; ELECTRON MICROSCOPY; ENTHALPY; FEMALE; GENE EXPRESSION PROFILING; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MOLECULAR PATHOLOGY; MOUSE; MUTAGENESIS; MUTATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TWO DIMENSIONAL ELECTROPHORESIS; AMINO ACID SUBSTITUTION; ANIMAL; BIOSYNTHESIS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MISSENSE MUTATION; PATHOLOGY;

AMINO ACID SUBSTITUTION; ANIMALS; APOLIPOPROTEIN E3; FEMALE; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; MALE; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 84904004360     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M048348     Document Type: Article

References (68)

1. Kypreos, K. E., and V. I. Zannis. 2006. LDL receptor defi ciency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J. Lipid Res. 47: 521-529.
2. Mahley, R. W., and S. C. Rall, Jr. 2001. Type III HLP (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, D. Valle, et al., editors. McGraw-Hill, New York. 2835-2862.
3. Kypreos, K. E., and V. I. Zannis. 2007. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem. J. 403: 359-367.
4. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-defi cient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
5. Schaefer, E. J., R. E. Gregg, G. Ghiselli, T. M. Forte, J. M. Ordovas, L. A. Zech, and H. B. Brewer, Jr. 1986. Familial apolipoprotein E defi ciency. J. Clin. Invest. 78: 1206-1219.
6. Reddick, R. L., S. H. Zhang, and N. Maeda. 1994. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14: 141-147.
7. Pitas, R. E., T. L. Innerarity, K. S. Arnold, and R. W. Mahley. 1979. Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fi broblasts: evidence for multiple receptor binding of apo-E HDLc. Proc. Natl. Acad. Sci. USA. 76: 2311-2315.
8. Innerarity, T. L., and R. W. Mahley. 1978. Enhanced binding by cultured human fi broblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 17: 1440-1447.
9. Herz, J., and T. E. Willnow. 1995. Lipoprotein and receptor interactions in vivo. Curr. Opin. Lipidol. 6: 97-103.
10. Kim, D. H., H. Iijima, K. Goto, J. Sakai, H. Ishii, H. J. Kim, H. Suzuki, H. Kondo, S. Saeki, and T. Yamamoto. 1996. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271: 8373-8380.
11. Takahashi, S., Y. Kawarabayasi, T. Nakai, J. Sakai, and T. Yamamoto. 1992. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specifi city. Proc. Natl. Acad. Sci. USA. 89: 9252-9256.
12. Rall, S. C., Jr., and R. W. Mahley. 1992. The role of apolipoprotein E genetic variants in lipoprotein disorders. J. Intern. Med. 231: 653-659.
13. Cash, J. G., D. G. Kuhel, J. E. Basford, A. Jaeschke, T. K. Chatterjee, N. L. Weintraub, and D. Y. Hui. 2012. Apolipoprotein E4 impairs macrophage efferocytosis and potentiates apoptosis by accelerating endoplasmic reticulum stress. J. Biol. Chem. 287: 27876-27884.
14. Hofmann, S. M., D. Perez-Tilve, T. M. Greer, B. A. Coburn, E. Grant, J. E. Basford, M. H. Tschop, and D. Y. Hui. 2008. Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-defi cient mice. Diabetes. 57: 5-12.
15. Kuhel, D. G., E. S. Konaniah, J. E. Basford, C. McVey, C. T. Goodin, T. K. Chatterjee, N. L. Weintraub, and D. Y. Hui. 2013. Apolipoprotein E2 accentuates postprandial infl ammation and diet-induced obesity to promote hyperinsulinemia in mice. Diabetes. 62: 382-391.
16. Kothapalli, D., I. Fuki, K. Ali, S. A. Stewart, L. Zhao, R. Yahil, D. Kwiatkowski, E. A. Hawthorne, G. A. FitzGerald, M. C. Phillips, et al. 2004. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J. Clin. Invest. 113: 609-618.
17. Moore, Z. W., B. Zhu, D. G. Kuhel, and D. Y. Hui. 2004. Vascular apolipoprotein e expression and recruitment from circulation to modulate smooth muscle cell response to endothelial denudation. Am. J. Pathol. 164: 2109-2116.
18. Moore, Z. W., and D. Y. Hui. 2005. Apolipoprotein E inhibition of vascular hyperplasia and neointima formation requires inducible nitric oxide synthase. J. Lipid Res. 46: 2083-2090.
19. Hui, D. Y., and J. E. Basford. 2005. Distinct signaling mechanisms for apoE inhibition of cell migration and proliferation. Neurobiol. Aging. 26: 317-323.
20. Getz, G. S., and C. A. Reardon. 2009. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J. Lipid Res. 50 ( Suppl ): S156-S161.
21. Zhu, Y., A. Kodvawala, and D. Y. Hui. 2010. Apolipoprotein E inhibits toll-like receptor (TLR)-3-and TLR-4-mediated macrophage activation through distinct mechanisms. Biochem. J. 428: 47-54.
22. Vezeridis, A. M., A. Chroni, and V. I. Zannis. 2011. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Ann. Med. 43: 302-311.
23. Chroni, A., T. J. Nieland, K. E. Kypreos, M. Krieger, and V. I. Zannis. 2005. SR-BI mediates cholesterol effl ux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol effl ux. Biochemistry. 44: 13132-13143.
24. Pham, T., A. Kodvawala, and D. Y. Hui. 2005. The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity. Biochemistry. 44: 7577-7582.
25. Nakashima, Y., E. W. Raines, A. S. Plump, J. L. Breslow, and R. Ross. 1998. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-defi cient mouse. Arterioscler. Thromb. Vasc. Biol. 18: 842-851.
26. Stannard, A. K., D. R. Riddell, S. M. Sacre, A. D. Tagalakis, C. Langer, A. von Eckardstein, P. Cullen, T. Athanasopoulos, G. Dickson, and J. S. Owen 2001. Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J. Biol. Chem. 276: 46011-46016.
27. Sacre, S. M., A. K. Stannard, and J. S. Owen. 2003. Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett. 540: 181-187.
28. Swertfeger, D. K., and D. Y. Hui. 2001. Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J. Biol. Chem. 276: 25043-25048.
29. Ishigami, M., D. K. Swertfeger, N. A. Granholm, and D. Y. Hui. 1998. Apolipoprotein E inhibits platelet-derived growth factorinduced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J. Biol. Chem. 273: 20156-20161.
30. Breslow, J. L., V. I. Zannis, T. R. SanGiacomo, J. L. Third, T. Tracy, and C. J. Glueck. 1982. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J. Lipid Res. 23: 1224-1235.
31. Havel, R. J., and J. P. Kane. 1973. Primary dysbetalipoproteinemia: predominance of a specifi c apoprotein species in triglyceride-rich lipoproteins. Proc. Natl. Acad. Sci. USA. 70: 2015-2019.
32. Zannis, V. I., D. Kardassis, and E. E. Zanni. 1993. Genetic mutations affecting human lipoproteins, their receptors, and their enzymes. Adv. Hum. Genet. 21: 145-319.
33. Hoffer, M. J., S. Niththyananthan, R. P. Naoumova, M. S. Kibirige, R. R. Frants, L. M. Havekes, and G. R. Thompson. 1996. Apolipoprotein E1-Hammersmith (Lys146 ? Asn;Arg147 ? Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia. Atherosclerosis. 124: 183-189.
34. Vezeridis, A. M., K. Drosatos, and V. I. Zannis. 2011. Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4. J. Lipid Res. 52: 45-56.
35. Kypreos, K. E., K. W. Van Dijk, Z. A. van Der, L. M. Havekes, and V. I. Zannis. 2001. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoproteintriglyceride secretion. J. Biol. Chem. 276: 19778-19786.
36. Chroni, A., T. Liu, I. Gorshkova, H. Y. Kan, Y. Uehara, A. von Eckardstein, and V. I. Zannis. 2003. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid effl ux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid effl ux in vitro and high density lipoprotein formation in vivo. J. Biol. Chem. 278: 6719-6730.
37. Liu, T., M. Krieger, H. Y. Kan, and V. I. Zannis. 2002. The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol effl ux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for effi cient lipid transport. J. Biol. Chem. 277: 21576-21584.
38. Kypreos, K. E., B. Teusink, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2001. Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer. FASEB J. 15: 1598-1600.
39. Fotakis, P., A. K. Kateifi des, C. Gkolfi nopoulou, D. Georgiadou, M. Beck, K. Gr̈ndler, A. Chroni, E. Stratikos, D. Kardassis, and V. I. Zannis. 2013. Role of the hydrophobic and charged residues in the218-226 region of apoA-I in the biogenesis of HDL. J. Lipid Res. 54: 3281-3292. [Erratum. 2014. J. Lipid Res. 55: 163. ]
40. Luo, J., Z. L. Deng, X. Luo, N. Tang, W. X. Song, J. Chen, K. A. Sharff, H. H. Luu, R. C. Haydon, K. W. Kinzler, et al. 2007. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2: 1236-1247.
41. Thorngate, F. E., P. G. Yancey, G. Kellner-Weibel, L. L. Rudel, G. H. Rothblat, and D. L. Williams. 2003. Testing the role of apoA-I, HDL, and cholesterol effl ux in the atheroprotective action of lowlevel apoE expression. J. Lipid Res. 44: 2331-2338.
42. Chroni, A., A. Duka, H. Y. Kan, T. Liu, and V. I. Zannis. 2005. Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase defi-ciency. Biochemistry. 44: 14353-14366.
43. Lusis, A. J., B. A. Taylor, D. Quon, S. Zollman, and R. C. LeBoeuf. 1987. Genetic factors controlling structure and expression of apolipoproteins B and E in mice. J. Biol. Chem. 262: 7594-7604.
44. Kypreos, K. E., X. Li, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2003. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 42: 9841-9853.
45. Koukos, G., A. Chroni, A. Duka, D. Kardassis, and V. I. Zannis. 2007. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. Biochem. J. 406: 167-174.
46. Timmins, J. M., J. Y. Lee, E. Boudyguina, K. D. Kluckman, L. R. Brunham, A. Mulya, A. K. Gebre, J. M. Coutinho, P. L. Colvin, T. L. Smith, et al. 2005. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115: 1333-1342.
47. Lalazar, A., K. H. Weisgraber, S. C. Rall, Jr., H. Giladi, T. L. Innerarity, A. Z. Levanon, J. K. Boyles, B. Amit, M. Gorecki, R. W. Mahley, et al. 1988. Site-specifi c mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem. 263: 3542-3545.
48. Lalazar, A., and R. W. Mahley. 1989. Human apolipoprotein E. Receptor binding activity of truncated variants with carboxylterminal deletions. J. Biol. Chem. 264: 8447-8450.
49. Ji, Z. S., S. Fazio, and R. W. Mahley. 1994. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269: 13421-13428.
50. Horie, Y., S. Fazio, J. R. Westerlund, K. H. Weisgraber, and S. C. Rall, Jr. 1992. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267: 1962-1968.
51. Chappell, D. A. 1989. High receptor binding affi nity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia). J. Clin. Invest. 84: 1906-1915.
52. Hui, D. Y., T. L. Innerarity, and R. W. Mahley. 1984. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E. J. Biol. Chem. 259: 860-869.
53. Drosatos, K., D. Sanoudou, K. E. Kypreos, D. Kardassis, and V. I. Zannis. 2007. A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J. Biol. Chem. 282: 19556-19564.
54. Jong, M. C., V. E. Dahlmans, M. H. Hofker, and L. M. Havekes. 1997. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dosedependent manner. Biochem. J. 328: 745-750.
55. Rensen, P. C., and T. J. van Berkel. 1996. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicronlike triglyceride-rich lipid emulsions in vitro and in vivo. J. Biol. Chem. 271: 14791-14799.
56. Salinelli, S., J. Y. Lo, M. P. Mims, E. Zsigmond, L. C. Smith, and L. Chan. 1996. Structure-function relationship of lipoprotein lipasemediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. Functional importance of a properly folded surface loop covering the catalytic center. J. Biol. Chem. 271: 21906-21913.
57. Medh, J. D., S. L. Bowen, G. L. Fry, S. Ruben, M. Andracki, I. Inoue, J. M. Lalouel, D. K. Strickland, and D. A. Chappell. 1996. Lipoprotein lipase binds to low density lipoprotein receptors andinduces receptor-mediated catabolism of very low density lipoproteins in vitro. J. Biol. Chem. 271: 17073-17080.
58. Huang, Y., X. Q. Liu, S. C. Rall, Jr., J. M. Taylor, A. von Eckardstein, G. Assmann, and R. W. Mahley. 1998. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273: 26388-26393.
59. Koukos, G., A. Chroni, A. Duka, D. Kardassis, and V. I. Zannis. 2007. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry. 46: 10713-10721.
60. Miettinen, H. E., H. Gylling, T. A. Miettinen, J. Viikari, L. Paulin, and K. Kontula. 1997. Apolipoprotein A-IFin. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene. Arterioscler. Thromb. Vasc. Biol. 17: 83-90.
61. Zannis, V. I., A. Chroni, K. E. Kypreos, H. Y. Kan, T. B. Cesar, E. E. Zanni, and D. Kardassis. 2004. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr. Opin. Lipidol. 15: 151-166.
62. Wetterau, J. R., L. P. Aggerbeck, S. C. Rall, Jr., and K. H. Weisgraber. 1988. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem. 263: 6240-6248.
63. Wilson, C., M. R. Wardell, K. H. Weisgraber, R. W. Mahley, and D. A. Agard. 1991. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 252: 1817-1822.
64. Dong, L. M., C. Wilson, M. R. Wardell, T. Simmons, R. W. Mahley, K. H. Weisgraber, and D. A. Agard. 1994. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269: 22358-22365.
65. Dong, L. M., and K. H. Weisgraber. 1996. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271: 19053-19057.
66. Weisgraber, K. H. 1994. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45: 249-302.
67. Mahley, R. W., K. H. Weisgraber, and Y. Huang. 2006. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 103: 5644-5651.
68. Kypreos, K. E., P. Morani, K. W. Van Dijk, L. M. Havekes, and V. I. Zannis. 2001. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-defi cient mice. Biochemistry. 40: 6027-6035.